

Invenomic US Equity Long/Short UCITS Fund

Equity Long/Short

Performance Returns

The Invenomic US Equity Long/Short UCITS Fund returned -0.62% for the month of May (USD Institutional Pooled Share Class), net of fees.

Investment Objective & Strategy

Invenomic seeks to achieve long-term capital appreciation by investing both long and short in equities. The goal of the fund is to outperform U.S. equities over a market cycle with less volatility and drawdown.

The strategy utilises variable net exposures, with an expected average net between 40%-60% but that may be as low as 0% and as high as 80% in extreme market environments. Invenomic's net exposure is completely derived by security selection and is not intended to be a market timing tool. Gross exposure will generally be between 130%-200%.

The Manager



Monthly Performance – UCITS

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sept	Oct	Nov	Dec	Y-T-D
2025	-1.46%	1.91%	2.97%	-5.46%	-0.62%	-	-	-	-	-	-	-	-2.85%
2024	-2.67%	-7.26%	3.76%	0.58%	-1.40%	-4.83%	2.57%	-0.53%	-2.38%	0.71%	-0.08%	3.28%	-8.51%
2023	8.41%	-1.29%	2.49%	1.79%	-2.54%	-1.50%	1.51%	1.40%	1.32%	0.93%	0.12%	1.17%	14.28%
2022	12.96%	2.56%	2.59%	5.35%	5.24%	-5.13%	-0.27%	0.04%	-3.02%	5.20%	4.17%	2.08%	35.33%
2021	-	-	-	-	-	-	-	-	2.34%	-0.45%	2.59%	8.47%	13.37%

The performance figures quoted above represent the (net of fees) performance of the Invenomic US Equity Long/Short UCITS Fund, USD Founder Pooled Share Class, since launch on 16th September 2021, until 31 December 2021. Performance figures after 31 December 2021 represent the performance of the USD Institutional Pooled Share Class. These performance figures refer to the past and past performance is not a reliable guide to future performance.

Monthly Performance – Invenomic Fund LP (Non-UCITS)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sept	Oct	Nov	Dec	Y-T-D
2025	-1.50%	1.74%	3.30%	-5.30%	-0.58%	-	-	-	-	-	-	-	-2.54%
2024	-2.35%	-7.22%	3.73%	0.66%	-1.49%	-5.13%	2.78%	0.15%	-2.23%	0.82%	-0.27%	3.51%	-7.39%
2023	8.24%	-1.39%	2.30%	2.08%	-2.59%	-1.56%	1.43%	1.52%	1.48%	1.07%	0.16%	0.52%	13.65%
2022	16.94%	3.83%	2.78%	6.64%	5.72%	-5.65%	-0.69%	0.41%	-2.83%	4.89%	5.14%	2.46%	45.32%
2021	1.97%	9.55%	14.22%	2.40%	10.89%	-8.60%	1.79%	-0.51%	2.39%	-1.19%	3.23%	9.35%	53.16%
2020	-5.84%	-5.34%	-1.48%	9.55%	-3.81%	1.34%	0.39%	0.99%	-2.46%	3.41%	13.19%	3.45%	12.27%
2019	6.49%	0.24%	-1.43%	2.38%	-5.26%	3.33%	-1.45%	-5.98%	9.52%	0.14%	0.43%	2.56%	10.37%
2018	2.97%	0.51%	-1.43%	0.83%	-2.00%	-0.10%	0.19%	-1.49%	2.27%	1.34%	2.83%	-2.18%	3.61%
2017	-	-	-	-	-	-	-	0.57%	1.22%	0.24%	2.74%	2.62%	7.59%

Fund Facts

Structure	UCITS Fund
Domicile	Ireland
Valuation	Daily
Liquidity	Daily
Fund AUM	\$847 Million
Strategy AUM	\$2.1 Billion
Inception	September 16 th 2021

The performance figures quoted on the left represent the (net of fees, 1%/20%) performance of the Invenomic Fund LP, and is not of the Invenomic US Equity Long/Short UCITS Fund. UCITS Funds have to abide by certain investment restrictions and consequently the performance of the Invenomic US Equity Long/Short UCITS Fund may not be similar to that presented to the left. These performance figures refer to the past and past performance is not a reliable guide to future performance.

This is a marketing communication.

Portfolio Breakdown

Sector Allocation (%)	Long	Short	Net
Communication Services	7.83	-1.77	6.06
Consumer Discretionary	17.20	-16.10	1.10
Consumer Staples	3.39	-1.87	1.52
Energy	1.70	-1.24	0.46
Financials	12.45	-13.53	-1.08
Healthcare	17.04	-9.75	7.29
Industrials	17.62	-17.48	0.14
Information Technology	17.15	-23.44	-6.29
Materials	12.03	0.00	12.03
Real Estate	0.91	-4.36	-3.45
Utilities	0.00	0.00	0.00
Total	107.32	-89.52	17.80

Portfolio Characteristics	Long	Short
# of Positions	158	98
Median Position Size	0.53%	-0.77%
Price-to-Book Ratio	1.7x	18.9x
Price-to-Earnings Ratio	9.9x	47.2x
Enterprise Value-to-Sales Ratio	1.7x	8.9x

Market Cap Allocation (%)	Long	Short	Net
Large Cap (>\$5B)	34.35	-76.73	-42.38
Mid Cap (\$2B - \$5B)	37.37	-11.94	25.43
Small Cap (<\$2B)	35.59	-0.85	34.74
Total	107.32	-89.52	17.80

Invenomic US Equity Long/Short UCITS Fund

Equity Long/Short

Monthly Commentary

The Fund returned -0.62% for the month of May (USD Institutional Pooled Share Class), net of fees. Portfolio exposures at the end of the month stood at 107.32% long and -89.52% short, resulting in net exposure of 17.80% and gross exposure of 196.84%. The portfolio remains well diversified with 158 long positions and 98 short positions.

Equity markets bounced back sharply in May with growth outpacing value by over 500 basis points across mid- and large-cap stocks. Outside of mega-caps, value has underperformed growth again in 2025. As we have pointed out before, we are only observing strength in value stocks with the highest market capitalization as seen by the Russell Top 200 Index, which is the 200 largest names in the Russell 1000 Index. The remaining 800 names fall into the Russell Midcap Index where value has trailed growth this year by nearly 600 basis points. When disaggregating the return of the Russell 1000 Index in this manner, it becomes clear how substantial the impact of mega-cap value stocks has been this year.

Market capitalization dynamics have been sharply in favor of large caps since we launched the strategy. While we invest across the market capitalization spectrum, we will naturally have a bias to be long smaller capitalization companies because we are willing to buy attractive companies below \$1 billion in market cap, while we are reluctant to short overvalued companies at that size. For context, the ten largest companies in the market have a combined market capitalization of just over \$21 trillion, whereas the 1,065 companies with a market cap of less than \$1 billion have a combined market capitalization just under \$450 billion.

The momentum factor continued its strong start to the year, up again in May across all the benchmarks we track. We speak at length in our letters about the momentum factor and how it impacts our portfolio. CrowdStrike Holdings (CRWD) is an example of how momentum can perpetuate a stock's performance when the fundamentals suggest a very different reality. CRWD is a cybersecurity software company with a market capitalization of approximately \$115 billion, at the time of this writing. Over the past three years, forward earnings per share estimates have gone from \$3.38 to \$4.92 back down to \$3.44. During this period the stock price nearly tripled despite a forward EPS estimate down over 30% from its peak. Momentum continues to keep this stock performing well even though the underlying earnings forecast continues to fall. While this disconnect between price and fundamentals can be frustrating in the short term, we expect a reversion towards fair value in the foreseeable future.

While momentum continues to be a headwind for the long portfolio as well, we couldn't be more excited about the names we hold in the portfolio. Some other market participants appear to feel the same way, as we have had six takeover offers in our long portfolio so far in 2025. Foot Locker was a notable take out in May as Dick's Sporting Goods offered to buy the company for \$2.4 billion, more than an 80% premium to where it was trading in the market. While the names in our long portfolio may have bad price momentum, the underlying fundamentals are strong in our assessment. We believe that the recent flurry of takeover offers indicates that what we are seeing is being acknowledged by others.

The current form of momentum in the market began to perpetuate on February 2nd, 2023. During this period, gross exposure for hedge funds, as measured by Goldman Sachs, began to increase to levels that are at all-time highs. We suspect that hedge funds continue to lean into their positions as they increase their gross exposure. We believe that with hedge funds' gross exposure in the 99th percentile may be hitting a limit. When hedge funds begin to reduce their gross exposure, we believe momentum will reverse course. This will naturally happen by the covering of shorts (buying) and selling longs. Our portfolio primarily consists of undervalued long positions with bad price momentum and overvalued shorts with strong price momentum. While this positioning has been a headwind in the intermediate term, we expect it to pay rewards in the longer term.

Ali Motamed Portfolio Manager

Ali Motamed is the Founder, Managing Partner and Portfolio Manager of Invenomic Capital Management. Prior to founding Invenomic, Ali was Co-Portfolio Manager of the Boston Partners Long/Short Equity Fund. He was awarded Portfolio Manager of the Year in the Alternatives Category by Morningstar in 2014. Ali holds a B.A. in Economics with a Minor in Accounting from the University of California, Los Angeles, and a M.B.A. from Harvard Business School. He holds the Chartered Financial Analyst designation. He has twenty years of experience.

Ben Deschaine President

Ben is responsible for all non-investment related business activities at Invenomic. Ben began his investment career in 1998 and has experience in both mutual fund and hedge fund investing. Prior to Invenomic, he was Chief Investment Officer at Balter Liquid Alternatives, responsible for managing all aspects of the firm's mutual fund business. Before joining Balter Capital Management in 2012, Ben was a Managing Director at Sabretooth Capital Management, a global multi-strategy hedge fund affiliated with Tiger Management. Prior to Ben's time at Sabretooth, he spent ten years at Federal Street Advisors, a Boston based wealth management firm, leading their alternative investment research. He is a graduate of Bentley University with a B.S. and M.S. in Finance and holds the Chartered Alternative Investment Analyst designation.

Share Class	Institutional Pooled Class Shares	Retail Pooled Class Shares
Currency	USD, EUR, CHF, GBP	USD, EUR, CHF, GBP
Management Fee	1.00%	1.50%
Performance Fee	20.00%	20.00%
Min. Initial Subscription	1,000,000	1,000
ISIN Codes	USD: IE00BKFFVY943 EUR: IE00BKFFVYB67 GBP: IE00BKFFVYC74 CHF: IE00BKFFVYD81	USD: IE00BKFFVYF06 EUR: IE00BKFFVYG13 GBP: IE00BKFFVYH20 CHF: IE00BKFFVYJ44

Please note: The ISINs quoted on the left relate to Pooled share classes. There are non-Pooled share classes available and outlined in the Fund Supplement for clients whom can accommodate performance fee equalisation fee methodology. More details on performance fee methodology is outlined in the Fund's Supplement. All non-base currency share classes are hedged back to the base currency.

Contact Details

Investor Contact

Waystone Financial Investments Ltd
6th Floor, 125 Woodstreet
London, EC2V 7AN
T: +44 20 3997 2460
investmentsolutions@waystone.com

Management Company

Waystone Management Company (IE) Ltd
4th Floor, 35 Shelbourne Road, Ballsbridge
Dublin D04 A4E0, Ireland
T: +353 1 533 7020
investorrelations@waystone.com

Investment Manager

Invenomic Capital Management L.P.
211 Congress Street – 8th Floor
Boston, MA 02110
T: +1 (617) 729 2323
clientrelations@invenomic.com

Invenomic US Equity Long/Short UCITS Fund

Equity Long/Short

Disclaimer

RISK WARNING: Past performance is not a reliable indicator of future results, prices of investments and the returns from them may fall as well as rise. Investments in equities are subject to market risk. Changes in exchange rates may have an adverse effect on the value price or income of the product. The Investment Manager expects that a typical investor will be seeking to achieve a return on their investment in the long term and will be willing to accept the risks associated with an investment of this nature, which may be volatile. The Invenomic US Equity Long/Short UCITS Fund (the "Fund") may use higher leverage and financial derivative instruments as part of the investment process. The distribution of this report does not constitute an offer or solicitation and this notice shall not be construed as an offer of sale in any other fund managed or advised by Invenomic Capital Management or Waystone Management Company (IE) Ltd ("Waystone"). Any investment in the Fund should be based on the full details contained in the Fund's Supplement Prospectus and Key Investor Information Document which together with the Waystone website (<https://www.waystone.com/our-funds/waystone-managed-funds/>). Information given in this document has been obtained from, or based upon, sources believed by us to be reliable and accurate although neither Waystone nor Invenomic Capital Management L.P. accepts liability for the accuracy of the contents. The Representative in Switzerland is Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, 1005 Lausanne, Switzerland, whilst the Paying Agent is NPB Neue Privat Bank AG, Limmatquai 1/am Bellevue, P.O. Box, CH-8024 Zurich. In respect of the units distributed in or from Switzerland, the place of performance and jurisdiction is at the registered office of the Swiss representative. The basic documents of the Fund as well as the annual and, if applicable, semi-annual report may be obtained free of charge at the registered office of the Swiss Representative. Issued and approved by Waystone Management Company (IE) Ltd. Waystone does not offer investment advice or make recommendations regarding investments. The Manager of the Fund is Waystone Management Company (IE) Ltd, a company regulated by the Central Bank of Ireland. The Investment Manager for the fund, Invenomic Capital Management L.P. is authorised and regulated by the Securities Exchange Commission (the "SEC"). The Montlake UCITS Platform ICAV is registered and regulated as an open-ended Irish collective asset-management vehicle with segregated liability between sub-Funds formed in Ireland under the Irish Collective Asset management Vehicles Act 2015 and authorised by the Central Bank as a UCITS pursuant to the UCITS Regulations. This notice shall not be construed as an offer of sale in the Fund. Past performance is no indication of current or future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units. Authorised and Regulated by the Central Bank of Ireland. The Management Company may decide to terminate the arrangements made for the marketing of the Fund in accordance with Article 93a of Directive 2009/65/EC. To view the Summary of Investor Rights, please visit the following [link](#). This is a marketing communication.